Quantitative analysis of luciferase activity of viral and hybrid promoters in bovine preimplantation embryos

This study was conducted to investigate quantitatively the luciferase activity of gene constructs with viral and hybrid enhancers and promoters in bovine preimplantation embryos by using firefly luciferase reporter genes. In Experiment I, to examine the stability of the luciferase, bioluminescence intensity of bovine embryos injected with the luciferase gene driven by the SV40 early promoter and enhancer (SVEluc) was measured with a luminometer at 2 days after microinjection. The results indicated that the bioluminescence could be analysed at any time within 30 min because the luciferase activity was constant during the measurement period from 5 to 30 min. In Experiment II, the luciferase expression of fertilized oocytes injected with four gene constructs (TKEluc, TK6WEluc, SVEluc, and Miwluc) was analysed by using a photon imaging system at 2 or 6 days following microinjection. The results from Experiment II indicated that the reporter gene governed by the Miw promoter (RSV LTR and chicken β-actin promoter) was expressed more intensively in bovine morulae and blastocysts than three other gene constructs. In Experiment III, the effect of SV40 enhancer was investigated when fused downstream to the luciferase cDNA of the Miwluc vector. The results showed that SV40 enhancer further activated the luciferase activity of the Miw promoter in bovine preimplantation embryos. It was concluded, therefore, that the Miw promoter together with the SV40 enhancer would confer the strongest expression of the firefly luciferase reporter gene among the gene constructs tested in preimplantation bovine embryos. Mol. Reprod. Dev. 49:368–373, 1998. © 1998 Wiley-Liss, Inc.     

Engineering Viral Promoters for Gene Transfer to Human Neuroblasts

1. The strength and activity of several viral promoters in human neuroblasts were evaluated in vitro. 2. Several luciferase reporter gene contructs under the control of different viral promoters (HIV-1 LTR, HTLV-I LTR, MMTV LTR, RSV LTR, CMV, SV40), in the presence or in the absence of the viral SV40 enhancer, were transfected into two well-established human neural cell lines, including one derived from human embryonic olfactory cells (B4) and one derived from an adrenal neuroblastoma (SH-SY-5Y). The epithelial cell line HeLa was used as a control.3. The enzymatic activity of luciferase was evaluated after normalization with an internal control. The results indicated that in the context of the reporter gene constructs, the CMV promoter alone was, overall, the most active in any tested cell line. However, addition of the SV40 enhancer to the CMV promoter abolished luciferase activity in SH-SY-5Y cells while significantly increasing luciferase expression in the CNS derived B4 fetal neuroblasts.4. The results suggest that gene therapeutic vectors aimed to promote enzymatic activity through gene transfer into undifferentiated human neural cells are feasible. However, since differences in promoter activity in neuroectodermal-derived cells are very relevant, gene construct variants should be considered to optimize the system.     

不同异源启动子与MDVgB启动子及其复合启动子的活性比较

为了选择适宜的启动子调控外源基因的表达,以改善马立克氏病病毒为载体的重组病毒的免疫保护力。将hCMV立即早期启动子及增强子、SV40早晚期启动子及增强子或hCMV立即早期增强子的部分序列分别与马立克氏病病毒(MDV)自身的囊膜糖蛋白B基因(gB)启动子核心部分在体外杂合,分别构建复合启动子PhCMV-gB、PSV-gB或Pen-gB;将这些启动子与虫荧光素酶报告基因相连,构建表达载体。利用脂质体将以上质粒与内标质粒(pSV-β-LacZ)共转染鸡胚成纤维次代细胞,于转染后48h,将细胞刮下来,利用荧光素酶测定试剂盒和β-半乳糖苷酶测定试剂盒分别测定转染细胞的荧光素酶和β-半乳糖苷酶的活性,通过荧光素酶和β-半乳糖苷酶活性的比值获得虫荧光素酶的相对活性,利用虫荧光素酶的相对活性进行启动子的活性比较。结果表明,复合启动子相对马立克氏病病毒自身的gB启动子,活性有不同程度的提高,其中复合启动子PhCMV-gB的活性最高,而复合启动子PSV-gB和Pen-gB的活性相当;但与商业强启动子相比,复合启动子活性要弱一些或相当。因此,从某种意义上讲,这些复合启动子既具有gB启动子的一些特性,又有商业强启动子的一些特性,为以马立克氏病毒为载体的新兴疫苗的开发奠定了基础。     

几种肿瘤细胞中ezrin基因增强子区转录调控特性的研究

该文采用Western blot技术检测人食管癌EC109细胞、鼻咽癌CNE2细胞和宫颈癌HeLa细胞Ezrin蛋白的表达：采用DNA片段定向克隆技术构建一系列携带ezrin基因增强子区-1541／-706序列的报告基因表达载体,将载体瞬时转染EC109、CNE2和HeLa细胞,检测荧光素酶活性;研究肿瘤细胞中ezrin基因增强子区的转录调控特性。实验结果显示,在被检测的三种肿瘤细胞中,Ezfin蛋白的表达水平没有明显不同。Ec109细胞中,当ezrin基因-1541／-706N段正向位于无启动子的报告基因上游时,表现出类似启动子的转录激活作用：当这一片段反向连接时转录激活作用几乎消失。当-1541／-706片段正向位于ezrin启动子或SV40启动子上游时,显著增强荧光素酶表达;然而,当这一片段反向位于启动子上游以及正向或反向位于启动子控制的报告基因下游时,转录增强作用消失。ezrin基因-1541／-706N段在CNE2和HeLa细胞中的转录调控作用,与其在EC109细胞中的转录调控作用部分相似,但不完全相同。结果表明,ezrin基因增强子区具有转录激活和转录增强双重作用,这种作用具有DNA序列位置和方向依赖性以及细胞特异性。     

A33启动子结肠癌特异性探究及SV40增强子对其转录活性影响

为了探究A33核心启动子结肠癌特异性及SV40增强子对其转录水平的影响,该研究通过构建A33核心启动子和带SV40增强子的A33核心启动子(eA33)的荧光素酶报告基因载体pGL3-A33和pGL3-eA33,与内参照pRL-SV40质粒共转染至不同的细胞系中,利用双荧光素酶检测系统检测分析了A33和eA33启动子在不同细胞系中的转录活性。结果显示,A33核心启动子在结肠癌细胞系中具有转录活性低,但结肠癌特异性好的特点,而在其他类型癌细胞中基本没有活性。同时发现,eA33在各类癌细胞中的转录水平与A33相比,均呈大幅度提高,有显著性差异(P<0.01),但SV40增强子能显著增强A33启动子转录活性的同时减低了其结肠癌特异性。这为靶向癌症基因—病毒治疗策略在结肠癌的生物治疗应用中寻找结肠癌特异性的启动子奠定了研究基础。     

Comparison of CMV, RSV, SV40 viral and Vlambda1 cellular promoters in B and T lymphoid and non-lymphoid cell lines.

Determining the activity of viral and cellular regulatory elements in B or T lymphoid cell lines would facilitate appropriate utilization of the regulatory sequences for gene transfer- and expression-dependent applications. We have compared the activity of the CMV, RSV and SV40 viral promoter/enhancers as well as the Vlambda1 cellular promoter, in three B cell lines (REH, SMS-SB, C3P), three T cell lines (CEM, Jurkat, ST-F10), and two non-lymphoid cell lines (K-562, HeLa) using the luciferase reporter gene. In B cell lines, the activity of the CMV promoter/enhancer construct was the highest ranging from 10- to 113-fold greater than that of SV40. In contrast, in T cell lines the RSV promoter/enhancer activity was 11-65-fold higher than that of SV40. The Vlambda1 promoter activity was close to that of SV40 promoter/enhancer in most of the cell lines tested. We conclude that CMV and RSV promoter/enhancers contain stronger regulatory elements than do the SV40 and Vlambda1 for expression of genes in lymphoid cell lines.     

Effect of cyclosporin A treatment on the in vivo regulation of type I MHC gene expression.

Rat soleus muscle consists predominantly of slow type I fibers. We have shown previously through deletion analysis that the highest level of reporter activity that we measure when injecting type I myosin heavy chain (MHC) promoter (MHC(1))-linked luciferase plasmid into soleus muscles depends on the presence of a 550-bp upstream enhancer (3,450-2,900) region of the promoter. Because the calcineurin-nuclear factor of activated T cells (NFAT) pathway has been implicated in the regulation of the slow muscle gene program, particularly the MHC(1) isoform, and the MHC(1) promoter contains several putative NFAT sites, we examined via deletion and mutation analyses whether this pathway is involved in the regulation of promoter activity in soleus. Nine days of treatment with the calcineurin inhibitor cyclosporin A (CsA) caused a significant decrease in activity of the -3,500- and -3,450-bp promoters compared with vehicle-treated rats. Truncation of the promoter to -2,900 bp or smaller reduced the activity and also eliminated the CsA responsiveness, thus implying that the enhancer region is required for CsA responsiveness. Surprisingly, mutating the two NFAT elements within the enhancer region had no obvious effect on promoter activity. CsA treatment resulted in an increase in the mRNA levels of fast-type IIa and IIx MHC isoforms, but RT-PCR analysis of MHC(1) pre-mRNA and mature mRNA expression in soleus muscles revealed no differences between vehicle- and CsA-treated rats. Although CsA affects the activity of the MHC(1) promoter, it appears that its effect is not through direct binding of NFAT to sites on the promoter.     

A cell type-specific enhancer drives expression of the chick muscle acetylcholine receptor alpha-subunit gene

The regulation of acetylcholine receptor alpha-subunit gene expression was analyzed by transient expression assays. Using rabbit beta-globin cDNA as a reporter gene, we have confirmed that the 5'-flanking sequence of the chicken acetylcholine receptor alpha-subunit gene directs specific expression in differentiated C2C12 cells, a mouse muscle cell line, but not in undifferentiated C2C12 cells and mouse 3T3 fibroblasts. Testing chimeric plasmids containing Bal31 deletion mutants of the alpha-subunit gene upstream sequence, we found the -116 to -81 region of the alpha-subunit to be responsible for tissue- and stage-specific expression. This 36 bp fragment stimulates the activity of both alpha-subunit and SV40 promoters in a distance- and orientation-independent manner, thus fulfilling the criteria of an enhancer.     

Novobiocin inhibits the SV40 enhancer activity

Using a transient expression assay, we have analysed the effect of novobiocin, DNA topoisomerase II inhibitor, on simian virus 40(SV40) enhancer activities. We used the recombinant clones containing type I or II collagen promoters placed upstream of the bacterial chloramphenicol acetyltransferase (CAT) gene with or without SV40 enhancer. We observed the expected increase in CAT activities due to the presence of the SV40 enhancer. Interestingly, CAT gene expression of the enhancer-containing constructs were inhibited more sensitively by novobiocin than that of the enhancer-less construct. This findings lead us propose that DNA superhelicity mediated by topoisomeraseII is one of the important factor for the manifestation of SV40 enhancer activity.     

携带不同数量增强子的嵌合型肝脏特异性启动子的构建及其体外实验研究

通过PCR手段成功获得肝细胞特异性启动子人α1-抗胰蛋白酶启动子hAATp(human α1-antitrypsin promoter,hAATp)及具有增强子功能的肝脏特异的肝调控区HCR (hepatic control region,HCR)。在此基础上,通过分子克隆手段构建获得携带有不同数量的HCR增强子的嵌合型肝脏特异性hAAT启动子,并在下游连入报告基因Luciferase,然后将重组质粒转染人肝癌细胞系HepG2、小鼠肝癌细胞系Hepa1-6、人胚肾细胞系HEK293和人脑星形胶质母细胞瘤细胞系U87-MG,通过检测Luciferase表达活性分析携带不同数量增强子的肝脏特异性启动子的启动活性及其组织特异性。结果表明,携带有3个增强子的嵌合型肝脏特异性启动子活性及特异性最好,为肝脏类疾病的靶向性治疗研究奠定了基础。